Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer.

Saved in:

Bibliographic Details
Title:	Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer.
Authors:	Posch, Doris¹, Fuchs, Hannah¹, Kornek, Gabriela¹, Grah, Anja¹, Pammer, Johannes², Aretin, Marie-Bernadette³, Fuereder, Thorsten¹
Source:	Scientific Reports. 9/9/2016, p32946. 1p.
Database:	Academic Search Ultimate

Be the first to leave a comment!